Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma: Effect on human immunodeficiency virus and serum interleukin-6 levels over time

Cancer

Volumn 78, Issue 3, 1996, Pages 517-526

  Levine, Alexandra M ^a   Tulpule, Anil ^a   Espina, Byron ^a   Boswell, William ^a   Buckley, Jonathan ^a   Rasheed, Suraiya ^a   Stain, Steven ^a   Parker, John ^a   Nathwani, Bharat ^a   Gill, Parkash S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS related lymphoma; Human immunodeficiency virus; interleukin 6; M BACOD chemotherapy; zalcitabine

Indexed keywords

ANTIGEN P24; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; METHOTREXATE; VINCRISTINE; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HIV CORE PROTEIN P24; HIV-1; HUMANS; INTERLEUKIN-6; LEUCOVORIN; LYMPHOMA, AIDS-RELATED; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; REMISSION INDUCTION; VINCRISTINE; ZALCITABINE;

EID: 8944257614     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<517::AID-CNCR20>3.0.CO;2-0     Document Type: Article

References (38)

1. Ross R, Dworsky R, Paganini-Hill A, Levine AM, Mack T. Non-Hodgkin's lymphoma in never married men in Los Angeles. Br J Cancer 1985;52:785-7.
2. Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. Ann Intern Med 1985;103:402.
3. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin's lymphoma. Lancet 1991;337:805-9.
4. Peters BS, Beck EJ, Coleman DG. Changing disease patterns in patients with AIDS in a referral center in the United Kingdom: the changing face of AIDS. Br Med J 1991;302:203-7.
5. Rabkin CS, Biggar RJ, Horm JW. Increasing incidence of cancers associated with the human immunodeficiency virus epidemic. Int J Cancer 1991;47:692-6.
6. Gail MH, Pluda JM, Rabkin CS. Projections of the incidence of non-Hodgkin's lymphoma related to Acquired Immunodeficiency Syndrome. J Natl Cancer Inst 1991;83:695-701.
7. Pluda JM, Venzon DJ, Tosato G. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993;11:1099-107.
8. Kaplan LD, Abrams DI, Feigal E. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-24.
9. Gill PS, Levine AM, Krailo M. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987;5:1322-8.
10. Dugan M, Subar M, Odajnyk C. Intensive multiagent chemotherapy for AIDS related diffuse large cell lymphoma. Blood 1986;68:124a.
11. Levine AM, Wernz JC, Kaplan L. Low dose chemotherapy with central nervous system prophylaxis and azidothymidine maintenance in AIDS-related lymphoma: a prospective multi-institutional trial. JAMA 1991;266:84-8.
12. Yarchoan R, Perno CF, Thomas RV. Phase I studies of 2′,2′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine. Lancet 1988;i:76-80.
13. Fauci A, Schnittman SM, Poli G. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:678-93.
14. Tohyama N, Karasuyama H, Tada T. Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA. J Exp Med 1990; 171:389-400.
15. Kawano M, Hirano T, Matsuda T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
16. Yoshizaki K, Matsuda T, Nishimoto N. Pathogenic significance of IL-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
17. Fischl MA, Olson RM, Follansbee SE. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9.
18. Johnson IS, Armstrong JG, Gorman M. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963;23:1390-427.
19. Turner RR, Boone DC, Levine AM. Flow cytometric lymphocyte immunophenotyping in homosexual men with the persistent generalized lymphadenopathy syndrome. A longitudinal study of lymph nodes and blood. Diagn Clin Immunol 1987;5:194-200.
20. Louie S, Cai J, Law R, Lin G, Lunardi-Iskandar Y, Jung B, Masood R, Gill PS. The effect of Interleukin-1 and Interleukin-1 antagonist in AIDS-Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovir 1995;4:455-60.
21. Minitab Reference Manual. PC version, Release 8. (PA): Minitabb, Inc., State College, PA, 1991.
22. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in R X C contingency tables. JASA 1983;78:427-34.
23. SAS/STAT Users Guide, Release 6.03. Cary (NC): SAS Institute Inc., 1988.
24. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
25. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
26. Levine AM, Sullivan-Halley J, Pike MC. HIV-related lymphoma: prognostic factors predictive of survival. Cancer 1991;68:2466-72.
27. Ganzer A, Greher J, Volkers B. Inhibitory effect of Azidothymidine, 2′-3′ Dideoxyadenosine, and 2′,3′-dideoxycytidine on in vitro growth of hematopoietic proginator cells from normal persons and from patients with AIDS. Exp Hematol 1989;17:321-5.
28. Du DI, Volpe DA, Grieshabar CK, Murphy MJ. In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic proginator cells. Exp Hematol 1990;18:832-6.
29. Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991;5:195-214.
30. Kaplan L, Kahn J, Crowe S, Northfelt D, Neville P, Grossberg H, et al. Clinical and virologic effect of GM-CSF in patients receiving chemotherapy for HIV-associated non Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929-40.
31. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stemplen M, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA single amplification assay. J AIDS Hum Retrovir 1995;8:446-54.
32. Ballerini P, Gaidano G, Gong JZ. Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses 1992;8:731-5.
33. Emillie D, Coumbaras J, Raphael M. IL-6 production in high grade B lymphomas: correlation with presence of malignant immunoblasts in AIDS and in HIV-seronegative patients. Blood 1992;80:498-504.
34. Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood 1994;83:370-6.
35. Foss HD, Herbst H, Hummel M. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994;83:707-12.
36. Slyman DJ, Miller TP, Lippman SM. Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. J Clin Oncol 1990;8:986-93.
37. Emilie D, Marfaing A, Merrien D. Treatment of AIDS-lymphomas with an anti-IL-6 monoclonal antibody. Blood 1993;82:387a.
38. Beck JT, Hsu SM, Wijdenes J. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-Interleukin-6 antibody. N Engl J Med 1994;330:602-5.